What is ADMA Biologics's pre-tax income?

ADMA Biologics (ADMA) reported pre-tax income of $50.24M in Q2 2026.

How has ADMA Biologics's pre-tax income changed year-over-year?

ADMA Biologics's pre-tax income increased by 25.3% year-over-year, from $40.1M to $50.24M.

What is the long-term trend for ADMA Biologics's pre-tax income?

Over 3 years (2022 to 2025), ADMA Biologics's pre-tax income has grown at a 40.5% compound annual growth rate (CAGR), from -$65.9M to $182.66M.

What does pre-tax income mean?

Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

ADMA Biologics (ADMA) Pre-Tax Income

Screener

Pre-Tax Income at other companies

AbCellera Biologics Inc.ABCL

-$58.97M-62.2%

Lifecore Biomedical, Inc.LFCR

-$6.13M—

AnaptysBio, Inc.ANAB

-$52.84M-34.5%

Absci CorporationABSI

-$29.58M-12.3%

Avalo TherapeuticsAVTX

-$36.34M-75.1%

Apogee Therapeutics, Inc.APGE

-$74.03M-34.0%

Segments

By segment

See full

ADMA Bio Manufacturing$64.01M+41.6%

Plasma Collection Centers-$707K+38.6%

Other financials

Income statement

See full

Revenue$124.4M+2.0%

Gross profit$86.3M+28.3%

Operating income$52.4M+22.5%

Net income$37.8M+10.5%

EPS (diluted)$0.16+14.3%

Balance sheet

See full

Cash & equivalents$136.0M+50.7%

Total debt$203.9M+1,855%

Total equity$408.2M+2.5%

Total assets$684.2M+22.5%

Cash flow

See full

Operating cash flow$29.5M+39.7%

CapEx$2.3M-6.9%

Free cash flow$27.3M+45.8%

Valuation

See full

Market cap$2.25B-49.1%

Enterprise value$2.32B-46.6%

P/E13.3×-7.9×

P/S4.4×-4.9×

Profitability

See full

Gross margin64.7%+11.7pp

Operating margin43.8%+11.0pp

Net margin33%-11.1pp

FCF margin22.7%+8.9pp

Returns & leverage

See full

Return on equity41.9%-29.3pp

Debt / equity0.5×+0.5×

Current ratio7×+1.6×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 5:16 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001140361-26-031445

Line item	Three Months ended June 30, 2026	Three Months ended June 30, 2025	Six Months ended June 30, 2026	Six Months ended June 30, 2025
Loss on extinguishment of debt	-	(1,159)	-	(1,159)
Other expense	(22)	(108)	(161)	(172)
Other income (expense), net	(2,208)	(2,701)	(3,354)	(4,132)
INCOME BEFORE INCOME TAXES	50,237	40,097	107,365	73,546
Provision for income taxes	12,415	5,878	24,215	12,424
NET INCOME	$$37,822	$34,219	$83,150	61,122
BASIC EARNINGS PER COMMON SHARE	$$0.17	$0.14	$0.36	0.26
DILUTED EARNINGS PER COMMON SHARE	$$0.16	$0.14	$0.35	0.25

Item 1. Financial Statements.

FAQ

What is ADMA Biologics's pre-tax income?: ADMA Biologics (ADMA) reported pre-tax income of $50.24M in Q2 2026.
How has ADMA Biologics's pre-tax income changed year-over-year?: ADMA Biologics's pre-tax income increased by 25.3% year-over-year, from $40.1M to $50.24M.
What is the long-term trend for ADMA Biologics's pre-tax income?: Over 3 years (2022 to 2025), ADMA Biologics's pre-tax income has grown at a 40.5% compound annual growth rate (CAGR), from -$65.9M to $182.66M.
What does pre-tax income mean?: Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about ADMA Biologics's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

ADMA Biologics ADMA Pre-Tax Income

Pre-Tax Income at other companies

Segments

By segment

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about ADMA Biologics's pre-tax income.